Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)

Dongzhe Hong; Lei Si; Minghuan Jiang; Hui Shao; Wai kit Ming; Yingnan Zhao; Yan Li; Lizheng Shi

doi:10.1007/s40273-019-00833-1

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)

Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai kit Ming, Yingnan Zhao, Yan Li, Lizheng Shi

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

Original language	English
Pages (from-to)	1553
Number of pages	1
Journal	PharmacoEconomics
Volume	37
Issue number	12
DOIs	https://doi.org/10.1007/s40273-019-00833-1
State	Published - 1 Dec 2019

Access to Document

10.1007/s40273-019-00833-1

Fingerprint

Dive into the research topics of 'Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)'. Together they form a unique fingerprint.

Cite this

Hong, D., Si, L., Jiang, M., Shao, H., Ming, W. K., Zhao, Y., Li, Y., & Shi, L. (2019). Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9). PharmacoEconomics, 37(12), 1553. https://doi.org/10.1007/s40273-019-00833-1

Hong, Dongzhe ; Si, Lei ; Jiang, Minghuan et al. / Correction to : Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9). In: PharmacoEconomics. 2019 ; Vol. 37, No. 12. pp. 1553.

@article{182316bf292f4d6dbd5867851f16438d,

title = "Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)",

abstract = "The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.",

author = "Dongzhe Hong and Lei Si and Minghuan Jiang and Hui Shao and Ming, {Wai kit} and Yingnan Zhao and Yan Li and Lizheng Shi",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Switzerland AG.",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s40273-019-00833-1",

language = "English",

volume = "37",

pages = "1553",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "12",

}

Hong, D, Si, L, Jiang, M, Shao, H, Ming, WK, Zhao, Y, Li, Y & Shi, L 2019, 'Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)', PharmacoEconomics, vol. 37, no. 12, pp. 1553. https://doi.org/10.1007/s40273-019-00833-1

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9). / Hong, Dongzhe; Si, Lei; Jiang, Minghuan et al.
In: PharmacoEconomics, Vol. 37, No. 12, 01.12.2019, p. 1553.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)

AU - Hong, Dongzhe

AU - Si, Lei

AU - Jiang, Minghuan

AU - Shao, Hui

AU - Ming, Wai kit

AU - Zhao, Yingnan

AU - Li, Yan

AU - Shi, Lizheng

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

AB - The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

UR - http://www.scopus.com/inward/record.url?scp=85071765081&partnerID=8YFLogxK

U2 - 10.1007/s40273-019-00833-1

DO - 10.1007/s40273-019-00833-1

M3 - Comment/debate

C2 - 31485924

AN - SCOPUS:85071765081

SN - 1170-7690

VL - 37

SP - 1553

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 12

ER -

Hong D, Si L, Jiang M, Shao H, Ming WK, Zhao Y et al. Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9). PharmacoEconomics. 2019 Dec 1;37(12):1553. doi: 10.1007/s40273-019-00833-1